Publications

Manuscripts

Abstracts and Presentations

Abstracts and Presentations

  

  • Barnes, DA, Huston, M and Perez, HD. TNF-a and IL-1b cross-sensitization of astrocytes and astrocytoma cell lines.  J. Neuroimmunol, 1998 Vol 87:17-26. 
  • Barnes, DA, Huston, M, Benveniste, EN, et al. Induction of RANTES expression by astrocytes and astrocytoma cell lines.   Neuroimmunol, 1996 Vol 71:207-14. 
  • Lu HT, Huston M, Stark G and Ransohoff, R. Interferon-b acts downstream of IFN-g  induced class II transactivator messenger RNA accumulation to block  major histocompatibility complex class II gene expression and requires  the 48-kD DNA-binding protein, ISGF3-g. J Exp Med, 1995.Vol 182(5): 1517-25. 
  • Lee Y-J, Panek B, Huston M and Benveniste, EN. Role of protein kinase C and tyrosine kinase activity in IFN-g induced expression of the class II MHC gene. Am J Physiol, 1995.Vol 268 (1 pt 1): C127-37. 
  • Chong  KT and Huston M. Implications of endotoxin contamination in the  evaluation of antibodies to lipopolysaccharides in a murine model of  gram-negative sepsis. J Infect Disease, 1987, vol 156(5) 
  • Rodgers G, Huston M, et al. Serological characterization of an E. coli expressed 37-kilodalton T. pallidum antigen and gene localization. Infect and Immun, July 1986 
  • Hare  JF and Huston M. Virosome-mediated implantation of red cell band 3 into  the plasma membrane of cultured hepatoma cells .Exp Cell Research,  1985, vol. 161.
  • Hare  JF and Huston M. Degradation of exogenous membrane proteins implanted  into the plasma membranes of cultured hepatoma cells. Exp Cell Research,  1985, vol. 161 
  • Hare  JF and Huston M. Degradation of surface labeled hepatoma membrane  polypeptides:Effects of inhibitors.Arch Biochem and Biophys, Sept. 1984.  

Abstracts and Presentations

Abstracts and Presentations

Abstracts and Presentations

 

  • The Use of @RISK for Project in Biopharmaceutical Schedule Risk Assessment, Team Building and Strategic Planning. Palisade Health Risk Analysis Forum. San Diego, CA. Mar 31, 2010
  • eProtocols for eClinical Trials.With Hewlett-Packard.DIA E-Pharma Meeting: Enabling Clinical Research and Business in the  Biopharmaceutical Industry.Philadelphia, PA.Oct 21, 2002 
  • Applied Clinical Trials Conference.Clinical Team Decision Points (Oral Presentation). San Diego, CA.Sept. 29, 1999.
  • Williams GJ, Huston M, et al.Effects of BetaseronÒ on hepatitis B virus replication in HIV-infected individuals.J of Interferon Res, 1990.Vol 10, suppl 1:S14 
  • Williams  GJ, Huston M, et al.Correlation of increased serum neopterin levels and  suppression of HIV p24 antigen in AIDS patients receiving BetaseronÒ and AZT therapy.J of Interferon Res, 1990.Vol 10, suppl 1:S105.
  • Langton  B, Hancock M, Huston M, et al. The development and characterization of  antibodies to different regions of the c-erb-B2 protein on breast tumor  tissue and cell lines.Proc American Association of Cancer Research,  1989. Vol 30 
  • Hare  JF and Huston M. Metabolic degradation of the red cell anion  transporter implanted into the plasma membrane of dividing hepatoma  cells.UCLA Symbosia.J of Cellular Biochem, 1984 suppl 8A. 
  • Hare  JF, Huston M and Rich P. Differential turnover of exogenous membrane  polypeptides implanted into the hepatoma cell membrane.UCLA Symposia, J  of Cellular Biochem, 1983 Suppl 7B 
  • Hare  JF and Huston M. Virosome-mediated implantation of exogenous membrane  protein into the plasma membrane of cultured hepatoma cells.FASEB/ASBC  Proceedings, June 1983, San Francisco, CA